Treatment effects in multiple cognitive domains in Alzheimer’s disease: a two-year cohort study
Open Access
- 18 August 2014
- journal article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 6 (4) , 48
Abstract
Introduction: Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer’s disease (AD), little is known about the long term effects of cholinergic treatment on global cognitive function and potential specific effects in different cognitive domains. The objectives of this study were to determine the association between cholinergic treatment and global cognitive function over one and two years in a cohort of patients with mild or moderate AD and identify potential differences in domain-specific cognitive outcomes within this cohort. Methods: A cohort of patients meeting the revised National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for mild or moderate AD, including patients both on treatment with a cholinesterase inhibitor and untreated controls (treated = 65, untreated = 65), were recruited from the Cognitive Neurology Clinic at Sunnybrook Health Sciences Centre, as part of the Sunnybrook Dementia Study. Patients were followed for one to two years and underwent standardized neuropsychological assessments to evaluate global and domain-specific cognitive function. Associations between cholinesterase inhibitor use and global and domain-specific cognitive outcome measures at one and two years of follow-up were estimated using mixed model linear regression, adjusting for age, education, and baseline mini mental state examination (MMSE). Results: At one year, treated patients showed significantly less decline in global cognitive function, and treatment and time effects across tests of executive and visuospatial function. At two years, there was a significant trend towards less decline in global cognition for treated patients. Moreover, treated patients showed significant treatment and time effects across tests of executive functioning, memory, and visuospatial function. Conclusions: The present study offers two important contributions to knowledge of the effectiveness of cholinesterase inhibitor treatment in patients with mild-moderate AD: 1) that second-generation cholinesterase inhibitors demonstrate long-term effectiveness for reducing global cognitive decline over one to two years of follow-up, and 2) that decline in function for cognitive domains, including executive function, memory, and visuospatial skill that are primarily mediated by frontal networks and by the cholinergic system, rather than memory, may be slowed by treatment targeting the cholinergic system.Keywords
This publication has 77 references indexed in Scilit:
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohortInternational Psychogeriatrics, 2008
- A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2005
- The naming deficit in early Alzheimer's and vascular dementia.Neuropsychology, 1998
- Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's diseaseBehavioural Brain Research, 1997
- Learning and retention in preclinical and early Alzheimer's disease.Psychology and Aging, 1997
- Comparison of older people and patients with frontal lesions: Evidence from word list learning.Psychology and Aging, 1996
- Episodic and semantic memory in alzheimer's disease and progressive supranuclear palsy: A comparative studyJournal of Clinical and Experimental Neuropsychology, 1995
- Visuoconstructive performance and regional cerebral glucose metabolism in alzheimer's diseaseJournal of Clinical and Experimental Neuropsychology, 1991
- Behavioural observations during performance of the WAIS block design test related to abnormalities of regional cerebral blood flow in organic dementiaJournal of Clinical and Experimental Neuropsychology, 1986